Douglas R Lazzaro, MD, FAAO, FACS Chairman, Professor of Ophthalmology, The Richard C Troutman, MD, Distinguished Chair in Ophthalmology and Ophthalmic Microsurgery, Department of Ophthalmology, State University of New York Downstate Medical Center; Chief of Ophthalmology, Director of Cornea, Director of Surgical Training, Kings County Hospital Center
Douglas R Lazzaro, MD, FAAO, FACS is a member of the following medical societies: American Academy of Ophthalmology , American College of Surgeons , American Society of Cataract and Refractive Surgery , Association for Research in Vision and Ophthalmology , Association of University Professors of Ophthalmology , Brooklyn Ophthalmological Society, Cornea Society , New York Society for Clinical Ophthalmology, Ophthalmic Laser Surgical Society
Disclosure: Nothing to disclose.
The FDA approved ranibizumab (Lucentis) for diabetic macular edema in August 2012. Approval was based on the phase III trials, RIDE and RISE, 2 identically designed, parallel, double-blind, 3-year clinical trials, which were placebo-treatment–controlled for 24 months. A total of 759 patients were randomized into 3 groups to receive monthly treatment with mg ranibizumab (n=250), mg ranibizumab (n=252), or placebo injection (control group, n=257). Results showed subjects who received mg ranibizumab experienced significant, early (day 7), and sustained (24 months) improvements in vision (P < .01). 
Results. : The mean duration of CME before treatment with Ozurdex was months (range, 6–13 months). At baseline, the mean FT was ± μm. Mean (SD) values of FT did decrease to ± μm ( P = ) at month 1 and ± μm ( P = ) at month 3. Data on the 6-month follow-up showed a mild increase ± μm ( P = ). The mean (SD) change from baseline FT was μm (a decrease value of 35%) at month 1, and μm (decrease value of 41%) and μm (decrease value of 26%) at month 3 and month 6, respectively. The baseline BCVA data were ± logarithm of the minimum angle of resolution (logMAR). The mean BCVA improved to ± logMAR ( P = ) and ± logMAR ( P = ) after month 1 and month 3, respectively. At the last visit (6-month follow-up), the mean BCVA was ± logMAR ( P = ).